Post Profile






Medical News Today: Human antibody bolsters cancer drug performance

Some patients do not respond to the cancer drug rituximab, but breaking research finds that the addition of a human antibody reduces this resistance.
read more

share

Related Posts


Combination Of 2 Existing Drugs Appears Safe In Patients Who Have Not Responded To Previous Treatments For Resistant Lung Cancer

Health : Medical News Today

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tum...

New antibody appears to re-activate immune system in cancer therapy

Diseases & Conditions / Cancer : EurekAlert: Cancer

(Duke University Medical Center) Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a sm...

Lenalidomide Plus Rituximab Produces Durable Responses in Mantle Cell Lymphoma Patients in Phase 2 Study, Say Moffitt Cancer Center Researchers

Health : Newswise Medical News

TAMPA, Fla. - New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. The results...

Clinical Problems Tied To Antiphospholipid Antibodies May Be Improved By Rituximab

Health : Medical News Today

Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney...

Rituximab Shows Promise for Clinical Problems Tied to Antiphospholipid Antibodies

Health : Newswise Medical News

Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, according to a new study by resear...

Comments


Copyright © 2016 Regator, LLC